Amgen is rallying on hope surrounding a new class of PCSK9 inhibitors designed to reduce bad cholesterol.
Todd Campbell, The Motley Fool, The Motley Fool
Wed, 09/17/2014 - 10:46am
Amgen is rallying on hope surrounding a new class of PCSK9 inhibitors designed to reduce bad cholesterol.